RCC

16 registered clinical trials studyying RCC — 8 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	A Multicenter Real-World Study on TKI Therapy After Progression on First-Line TKI/IO Therapy or TKI/IO Therapy NCT07324876	Tianjin Medical University Cancer Institute and Hospital	—
Recruiting	Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cel NCT07300241	Neomorph, Inc	Phase 1
Recruiting	A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With S NCT06682793	A2 Biotherapeutics Inc.	Phase 1 / Phase 2
Not Yet Recruiting	A Prospective Registry Study of Stereotactic Ablative Radiotherapy (SABR) for Oligometastatic/Oligometastatic NCT06585878	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	N/A
Not Yet Recruiting	Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients NCT06577961	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Phase 1 / Phase 2
Recruiting	A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors NCT06259552	SparX Biotech(Jiangsu) Co., Ltd.	Phase 1
Recruiting	Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC) NCT05931393	University of Texas Southwestern Medical Center	Phase 2
Recruiting	Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study) NCT05917106	Jinling Hospital, China	—
Terminated	Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors NCT03875313	Calithera Biosciences, Inc	Phase 1 / Phase 2
Completed	A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies NCT03652077	Incyte Corporation	Phase 1
Withdrawn	Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma NCT03035630	Guru Sonpavde	Phase 2
Active Not Recruiting	A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) NCT02974738	Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Phase 1
Completed	Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy NCT03891485	National Cancer Institute, Naples	—
Terminated	Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC) NCT02447887	Fox Chase Cancer Center	Phase 1 / Phase 2
Active Not Recruiting	A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma ( NCT02293980	Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Phase 1
Unknown	Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma（RCC） NCT02072031	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 2